Sparrow Pharmaceuticals

Privately held: no public share price · United States

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 2
11-beta-HSD1Small molecule
Type 2 DiabetesCushing's Syndrome

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
December 2027 (1)
clofutribenPhase 2Type 2 Diabetes, Cortisol Excess
Est. primary completion 2027-12-31 · NCT07296484 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

8 June 2026Topline resultclofutribenPhase 2 study NCT02372578 in type 2 diabetes: HbA1c, glucose and total cholesterol reduced versus placebo at 6 weeks
Sparrow Pharmaceuticals · Source ↗

Financial reports

No financial reports recorded.